Patents
Literature
11 results about "Artificial antigen presenting cells" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Artificial antigen presenting cells (aAPCs) are a new technology and approach to cancer immunotherapy. Immunotherapy aims to utilize the body’s own defense mechanism—the immune system—to recognize mutated cancer cells and to kill them the way the immune system would recognize and kill a virus. Antigen presenting cells are the sentinels of the immune system and patrol the body for pathogens. When they encounter foreign pathogens, the antigen presenting cells alert the T cells—“the soldiers of the immune system”—that there is something foreign in the body with specific cell surface molecules. aAPCs are synthetic versions of these sentinel cells and are made by attaching the specific T-cell stimulating signals to various macro and micro biocompatible surfaces. This can potentially reduce the cost while allowing control over generating large numbers of functional pathogen-specific T cells for therapy. Activated and stimulated T cells can be studied in this biomimetic contex and used for adoptive transfer as an immunotherapy.
Scaffolds with stabilized MHC molecules for immune-cell manipulation
The present invention relates to artificial antigen presenting cell (aAPC) scaffolds to provide cells with specific functional stimulation to obtain phenotypic and functional properties ideal to mediate tumor regression or viral clearance. In particular, the scaffolds of the present invention comprise stabilized MHC class I molecules free of antigenic peptide. The scaffolds can be loaded with antigenic peptide on demand, providing an agile platform for effective expansion and functional stimulation of specific T cells in a peptide-MHC-directed fashion.
Owner:DANMARKS TEKNISKE UNIV
Injectable artificial antigen-presenting cells for immunotherapy
In various aspects and embodiments, this disclosure provides artificial antigen-presenting cells (aAPCs) suitable for parenteral administration for immunotherapy. In various embodiments, aAPCs effectively activate or inhibit target T cells, including CD8+ or CD4+ T cells, in vivo. The aAPCs according to this disclosure provide a storage-stable nanoparticle platform for immunotherapy. In various embodiments, the storage-stable nanoparticle platform controls characteristics such as particle size and particle chemistry, ligand design and ligand density, and aAPC aggregation tendency.
Owner:SERCOURI CO LTD
Synthetic viscoelastic activated cells for t cell engineering
Conventional CAR-T cell therapies have shown a significant success in the treatment of hematological cancers and lymphoma. However, this technique still has several problems, including cancer recurrence. Herein, a scalable technical platform is described to produce synthetic viscoelastic activated cells (SynVAC) with programmable mechanical and chemical activity as artificial antigen presenting cells (aAPC). The disclosure presented herein shows that the viscoelastic properties of the described SynVAC have great beneficial effects on expansion of T cells. For example, SynVAC exhibits robust improvements in T cell expansion, T memory stem cell (TMSC) formation, chimeric antigen receptor (CAR) transduction efficiency, tumor killing efficiency, and long-term in vivo persistence of CAR-T cells compared to conventional rigid or elastic microspheres.
Owner:RGT UNIV OF CALIFORNIA
Nanoparticles for delivery of immunoregulatory materials to t cells
PendingUS20260061054A1Antibody mimetics/scaffoldsGenetically modified cellsDiseaseMajor histocompatibility
Artificial antigen presenting cells (aAPC) including a major histocompatibility class II (MHC II) molecule and methods of their use for identifying, isolating, or detecting one or more antigen-specific T cells, and treating a disease, disorder, or condition, including cancer, are disclosed.
Owner:JOHNS HOPKINS UNIVERSITY
Engineered artificial antigen presenting cells and lipid nanoparticles for tumor infiltrating lymphocyte expansion
PCT designated stageWO2026050217A2Genetically modified cellsMammal material medical ingredientsCD86Costimulatory Molecule
In some embodiments, compositions and methods relating to isolated artificial antigen presenting cells (aAPCs) are disclosed, including aAPCs comprising a U937 cell modified to express one or more co-stimulatory molecules including CD64, CD86, 4-1BBL and / or OX40L. Further provided are lipid nanoparticles (LNPs) conjugated to one or more co-stimulatory molecules including CD64, CD86, 4-1BBL and / or OX40L. In some embodiments, methods of expanding tumor infiltrating lymphocytes (TILs) with aAPCs or LNPs and methods of treating cancers using TILs after expansion with aAPCs or LNPs are also disclosed.
Owner:IOVANCE BIOTHERAPEUTICS INC
Engineered artificial antigen presenting cells for tumor infiltrating lymphocyte expansion
ActiveUS12673982B2CD86CD58
In some embodiments, compositions and methods re¬lating to isolated artificial antigen presenting cells (aAPCs) are dis¬closed, including aAPCs comprising a myeloid cell transduced with one or more viral vectors, such as a MOLM-14 or a EM-3 myeloid cell, wherein the myeloid cell endogenously expresses HLA-A / B / C, ICOS-L, and CD58, and wherein the one or more viral vectors com¬prise a nucleic acid encoding CD86 and a nucleic acid encoding 4-1BBL and / or OX40L and transduce the myeloid cell to express CD86 and 4-1BBL and / or OX40L proteins. In some embodiments, methods of expanding tumor infiltrating lymphocytes (TILs) with aAPCs and methods of treating cancers using TILs after expansion with aAPCs are also disclosed.
Owner:IOVANCE BIOTHERAPEUTICS INC
Nanoparticles for delivery of immunoregulatory materials to t cells
Artificial antigen presenting cells (aAPC) including a major histocompatibility class II (MHC II) molecule and methods of their use for identifying, isolating, or detecting one or more antigen-specific T cells, and treating a disease, disorder, or condition, including cancer, are disclosed.
Owner:JOHNS HOPKINS UNIVERSITY
Engineered artificial antigen presenting cells and lipid nanoparticles for tumor infiltrating lymphocyte expansion
PCT designated stageWO2026050217A3Genetically modified cellsMammal material medical ingredientsAntigenCD86
In some embodiments, compositions and methods relating to isolated artificial antigen presenting cells (aAPCs) are disclosed, including aAPCs comprising a U937 cell modified to express one or more co-stimulatory molecules including CD64, CD86, 4-1BBL and / or OX40L. Further provided are lipid nanoparticles (LNPs) conjugated to one or more co-stimulatory molecules including CD64, CD86, 4-1BBL and / or OX40L. In some embodiments, methods of expanding tumor infiltrating lymphocytes (TILs) with aAPCs or LNPs and methods of treating cancers using TILs after expansion with aAPCs or LNPs are also disclosed.
Owner:IOVANCE BIOTHERAPEUTICS INC
Method for expansion of double negative regulatory T cells
There is provided herein a method for expanding human CD4−CD8− regulatory T cells (DN Tregs) from a population of cells comprising DN Tregs, comprising: culturing the population of cells with artificial antigen presenting cells (APCs), preferably the DN Tregs are αβ-TCR+CD56− or alternatively γδ-TCR+.
Owner:UNIV HEALTH NETWORK
Methods for identifying functional neoantigens and their use in cancer immunotherapy
PCT designated stageWO2026035444A8Biological material analysisAntineoplastic agentsAdoptive cellular therapyOncology
Disclosed are methods for identifying functional neoantigen peptides and using them in cancer immunotherapy. Candidate HLA-restricted peptides are derived e.g., from tumor mutations, loaded onto paramagnetic nano-artificial antigen-presenting cells (nano-aAPCs) that provide peptide- HLA (signal 1) and costimulatory ligands (signal 2), incubated with T cells, magnetically enriched, expanded in culture, and characterized for antigen specificity, phenotype, and function to select therapeutic peptides. The workflow supports peptide cocktails across Class I / IIHLA presentation for heterozygous subjects, and a wide binding¬ affinity range. Resulting T-cell products are enriched for central / effector memory and polyfunctional responses. The methods enable vaccines, polymeric aAPC therapeutics, adoptive cell therapies, and TCR- based biologies (e.g., bispecific T-cell engagers).
Owner:CELLKURE INC
Artificial antigen presenting cells comprising protein L for expanding immune cells for immunotherapy
Disclosed herein are methods of expanding immune cells for immunotherapy and / or increasing the purity of a population of CAR T cells using artificial antigen presenting cells (aAPCs) having on their surface Protein L. The disclosed aAPCs can also secrete antibodies that bind molecules of the T cell inhibitory pathway. For example, anti-CD3 scFv on the surface of the aAPCs can bind and activate T cells, while anti-CD28 scFv and 4-1BBL on the surface of the aAPCs can provide dual co-stimulation for the T cells resulting in decreased levels of the markers CD25, TIM3, LAG3, and PD1. For example, blocking PD1 / PDL1 ligation can limit suppression that is mediated by the tumor microenvironment. This is a less costly and more efficient alternative to peripheral blood mononuclear cells (PBMCs) and cytokine treatments that result in better quality T cell for adoptive transfer back into patients.
Owner:H LEE MOFFITT CANCER CENT & RES